The mechanism and consequences of BRAF inhibitor resistance in melanoma
- 31 July 2023
- journal article
- review article
- Published by Springer Nature in Genome Instability & Disease
- Vol. 4 (5) , 266-274
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82273460, 32260167)
- Yunnan Applied Basic Research Projects (202101AV070002)
- Key Laboratory of Tumor Immunological Prevention and Treatment in Yunnan Province, Yan'an Hospital Affiliated to Kunming Medical University (Grant No. KLTIPT-2023-02)
- Yunnan University (Grant No. 2023Y0222)
This publication has 64 references indexed in Scilit:
- PTEN at a glanceJournal of Cell Science, 2012
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretionNature, 2012
- The role of BRAF V600 mutation in melanomaJournal of Translational Medicine, 2012
- From genes to drugs: targeted strategies for melanomaNature Reviews Cancer, 2012
- Targeting the MAPK–RAS–RAF signaling pathway in cancer therapyExpert Opinion on Therapeutic Targets, 2012
- Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR PathwayPLOS ONE, 2011
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic ProfilingJournal of Clinical Oncology, 2011
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivationNature, 2010
- The landscape of somatic copy-number alteration across human cancersNature, 2010
- Mutations of the BRAF gene in human cancerNature, 2002